Dog study results
Extended-release bupivacaine has been studied in dog models as part of the development for human use. These studies were centered on the local and systemic safety and tolerability of the suspension in a dog model of inguinal hernia repair and reported similar macroscopic and microscopic findings in control and bupivacaine liposome injectable suspension-treated animals at day 15. There were no significant adverse effects on wound healing using bupivacaine liposome injectable suspension at doses higher than expected with clinical use in dogs.
This same group also investigated the effects of repeated doses of bupivacaine liposome injectable suspension in
dogs. Dogs were injected twice weekly for a total of eight injections with bupivacaine liposome injectable suspension (at doses higher than clinically recommended), bupivacaine HCl, or saline, administered into the subcutaneous tissue over the scapulae. There were no observed clinical signs consistent with CNS toxicity and no ECG abnormalities. In the bupivacaine liposome injectable suspension group, the only difference observed as compared to the other groups was macroscopic and microscopic indications of mild-to-moderate granulomatous inflammation. These observations were considered a normal response to the liposomes.
DOG INDICATION: For single-dose infiltration into the surgical site to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs.
IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for local infiltration injection in dogs only. Do not use in dogs younger than 5 months of age, that are pregnant, lactating or intended for breeding. Do not administer by intravenous or intra‐arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.
“We began using Nocita on canine patients undergoing cranial cruciate ligament stabilization surgeries and have been very pleased with the results. The product is intuitive to use and we have observed nothing but positive effects for our patients post-operatively. Specifically, these patients appear to bear more significant weight immediately post-op than usually expected, require very little rescue analgesia, and are willing to eat early in the recovery period which has allowed easy transition to oral medications. Nocita has quickly become standard protocol for analgesia on our canine cruciate ligament stabilization procedures.”Veterinary Surgeon
Other therapeutics from Aratana
Finally, appetite stimulation is in your control.
ENTYCE® (capromorelin oral solution) is the ONLY FDA-approved veterinary therapeutic designed to safely and effectively stimulate appetite in dogs. Administered orally once a day, ENTYCE is appropriate for treating inappetence caused by chronic and acute conditions.
IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.